This Beaten-Down Stock Just Gave Investors More Good News: Is it a Buy?

Slowly but surely, the company's prospects are looking more attractive.The past three years have been disappointing for Pfizer (PFE -0.74%): The drugmaker's revenue, earnings, and stock price have generally moved in the wrong direction. However, it hasn't been all bad -- Pfizer has made some progress on the clinical and regulatory fronts with several brand-new approvals.And now the company's financial results are improving. Let's look into Pfizer's latest quarterly update and decide whether its shares are w ...